Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 5, 2007, Pages 1741-1752

  Yasuda, Yasuki ^a   Kasahara, Kei ^a   Mizuno, Fumiko ^a   Nishi, Kazuyuki ^a   Mikasa, Keiichi ^a   Kita, Eiji ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MACROLIDE; MATRILYSIN; PNEUMOLYSIN; ROXITHROMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL VIRULENCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; FEEDING; IN VITRO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; WESTERN BLOTTING;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; LUNG; MACROLIDES; MALE; MATRIX METALLOPROTEINASE 7; MICE; MICE, INBRED CBA; PNEUMONIA, PNEUMOCOCCAL; ROXITHROMYCIN; STREPTOLYSINS;

EID: 34248368413     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01459-06     Document Type: Article

References (47)

1. Abe, S., H. Nakamura, S. Inoue, H. Saito, S. Kato, N. Mukaida, K. Matsushima, and H. Tomoike. 2000. Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 22:51-60.
2. Abeyama, K., K. Kawahara, S. Iino, T. Hamada, S. Arimura, K. Matsushita, T. Nakajima, and I. Maruyama. 2003. Antibiotic cyclic AMP signaling by "primed" leukocytes confers anti-inflammatory cytoprotection. J. Leukoc. Biol. 74:908-915.
3. Alexander, C. M., F. Reichsman, M. T. Hinkes, J. Lincecum, K. A. Becker, S. Cumberledge, and M. Bernneld. 2000. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat. Genet. 25:329-332.
4. Allen, B. L., B. Katz, and M. Hook. 2002. Streptococcus anginosus adheres to vascular endothelium basement membrane and purified extracellular matrix proteins. Microb. Pathog. 32:191-204.
5. Anzueto, A., M. S. Niederman, G. S. Tillotson, and the Bronchitis Study Group. 1998. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Clin. Ther. 20:885-900.
6. Auten, R. L., M. H. Whorton, and N. S. Mason. 2002. Blocking neutrophil influx reduces DNA damage in hyperoxia-exposed newborn rat lung. Am. J. Respir. Cell Mol. Biol. 26:391-397.
7. Bui, K. Q., M. A. Banevicius, C. H. Nightingale, R. Quintiliani, and D. P. Nicolau. 2000. In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa. J. Antimicrob. Chemother. 45:57-62.
8. Culić, O., V. Erakovic, and M. J. Parnham. 2001. Anti-inflammatory effects of macrolide antibiotics. Eur. J. Pharmacol. 429:209-229.
9. Dunsmore, S. E., U. K. Saarialho-Kere, J. D. Roby, C. L. Wilson, L. M. Matrisian, H. G. Welgus, and W. C. Parks. 1998. Matrilysin function and expression in airway epithelium. J. Clin. Investig. 102:1321-1331.
10. Edwards, D., C. Parfett, and D. Denhardt. 1985. Transcriptional regulation of two serum-induced RNAs in mouse fibroblasts. Mol Cell Biol. 5:3280-3288.
11. Finch, R. 2001. Community-acquired pneumonia: the evolving challenge. Clin. Microbiol. Infect. 7(Suppl. 3):30-38.
12. Fukuda, Y., K. Yanagihara, Y. Higashiyama, Y. Miyazaki, Y. Hirakata, H. Mukae, K. Tomono, Y. Mizuta, K. Tsukamoto, and S. Kohno. 2006. Effects of macrolides against pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur. Respir. J. 27:1020-1025.
13. Gemmell, C. G., and M. McLeod. 1992. The effect of roxithromycin on the virulence of gram-positive cocci. Diagn. Microbiol. Infect. Dis. 15(Suppl. 1):67S-70S.
14. Gibbs, D. F., R. L. Warner, S. J. Weiss, K. J. Johnson, and J. Varani. 1999. Characterization of matrix metalloproteinases produced by rat alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 20:1136-1144.
15. Hamada, K., E. Kita, M. Sawaki, K. Mikasa, and N. Narita. 1995. Antitumor effect of erythromycin in mice. Chemotherapy 41:59-69.
16. Hamada, K., K. Mikasa, Y. Yunou, T. Kurioka, T. Majima, N. Narita, and K. Kita. 2000. Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer. Chemotherapy 46:49-61.
17. Haro, H., H. C. Crawford, B. Fingleton, J. R. MacDougall, K. Shinomiya, D. M. Spengler, and L. M. Matrisian. 2000. Matrisian, matrix metalloproteinase-3-dependent generation of a macrophage chemoattractant in a model of herniated disc resorption. J. Clin. Investig. 105:133-141.
18. Hashimoto, N., T. Kawabe, T. Hara, T. Imaizumi, H. Wakayama, H. Saito, K. Shimokata, and Y. Hasegawa. 2001. Effect of erythromycin on matrix metalloproteinase-9 and cell migration. J. Lab. Clin. Med. 137:176-183.
19. Hirakata, Y., M. Kaku, R. Mizukane, K. Ishida, N. Furuya, T. Matsumoto, K. Takeda, and K. Yamaguchi. 1992. Potential effects of erythromycin on host defense systems and virulence of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 36:1922-1927.
20. Hoffman, H. L., M. E. Klepser, E. J. Ernst, C. R. Petzold, L. M. Sa'adah, and G. V. Doern. 2003. Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. Antimicrob. Agents Chemother. 47:739-746.
21. Kanai, K., K. Asano, T. Hisamitsu, and H. Suzaki. 2004. Suppression of matrix metalloproteinase production from nasal fibroblasts by macrolide antibiotics in vitro. Eur. Respir. J. 23:671-678.
22. Kasahara, K., E. Kita, K. Maeda, K. Uno, K. Takahashi, M. Konishi, E. Yoshimoto, K. Murakawa, E. Kita, and H. Kimura. 2005. Macrolide resistance of Streptococcus pneumoniae isolated during long-term macrolide therapy: difference between erythromycin and clarithromycin. J. Infect. Chemother. 11:112-114.
23. Kasahara, K., K. Maeda, K. Mikasa, K. Uno, K. Takahashi, M. Konishi, E. Yoshimoto, K. Murakawa, E. Kita, and H. Kimura. 2005. Clonal dissemination of macrolide-resistant and penicillin-susceptible serotype 3 and penicillin-resistant Taiwan 19F-14 and 23F-15 Streptococcus pneumoniae isolates in Japan: a pilot surveillance study. J. Clin. Microbiol. 43:1640-1645.
24. Kawashima, M., J. Yatsunami, Y. Fukuno, M. Nagata, M. Tominaga, and S. Hayashi. 2002. Inhibitory effects of 14-membered ring macrolide antibiotics on bleomycin-induced acute lung injury. Lung 180:73-89.
25. Kita, E., K. Mikasa, and K. Kasahara. 2003. Syndecan shedding from epithelial cells affects host defense against respiratory infection. Int. Congr. Ser. 1257:21-26.
26. Kobayashi, M., T. Shimauchi, R. Hino, and Y. Tokura. 2004. Roxithromycin downmodulates Th2 chemokine production by keratinocytes and chemokine receptor expression on Th2 cells: its dual inhibitory effects on the ligands and the receptors. Cell. Immunol. 228:27-33.
27. Kobayashi, T., K. Tateda, T. Matsumoto, S. Miyazaki, A. Watanabe, T. Nukiwa, and K. Yamaguchi. 2002. Macrolide-treated Pseudomonas aeruginosa induces paradoxical host responses in the lungs of mice and a high mortality rate. J. Antimicrob. Chemother. 50:59-66.
28. Konno, S., K. Asano, M. Kurokawa, K. Ikeda, K. Okamota, and M. Adachi. 1994. Antiasthmatic activity of a macrolide antibiotic, roxithromycin: analysis of possible mechanisms in vitro and in vivo. Int. Arch. Allergy Immunol. 105:308-316.
29. Labro, M. T. 2004. Cellular and molecular effects of macrolides on leukocyte function. Curr. Pharm. Des. 10:3067-3080.
30. Li, Q., P. W. Park, C. L. Wilson, and W. C. Parks. 2002. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111:635-646.
31. Lonks, J. R., J. Garau, L. Gomez, M. Xercavins, A. O. de Echaguen, I. F. Gareen, P. T. Reiss, and A. A. Medeiros. 2002. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 35:556-564.
32. Lonks, J. R., J. Garau, and A. A. Medeiros. 2002. Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides. J. Antimicrob. Chemother. 50(Suppl. S2):87-92.
33. Lopez-Boado, Y. S., C. L. Wilson, L. V. Hooper, J. I. Gordon, S. J. Hultgren, and W. C. Parks. 2000. Bacterial exposure induces and activates matrilysin in mucosal epithelial cells. J. Cell Biol. 148:1305-1315.
34. Mandell, L. A., J. G. Bartlett, S. F. Dowell, T. M. File, Jr., D. M. Musher, and C. Whitney. 2003. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37:1405-1433.
35. Mizukane, R., Y. Hirakata, M. Kaku, Y. Ishii, N. Furuya, K. Ishida, H. Koga, S. Kohno, and K. Yamaguchi. 1994. Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 38:528-533.
36. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5, 5th ed. National Committee for Clinical Laboratory Standards, Villanova, Pa.
37. Newman, S. L., and M. A. Tucci. 1990. Regulation of human monocyte/ macrophage function by extracellular matrix. Adherence of monocytes to collagen matrices enhances phagocytosis of opsonized bacteria by activation of complement receptors and enhancement of Fc receptor function. J. Clin. Investig. 86:703-714.
38. Park, P. W., G. B. Pier, M. T. Hinkes, and M. Bernfield. 2001. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 411:98-102.
39. Patel, K. B., D. Xuan, P. R. Tessier, J. H. Russomanno, R. Quintiliani, and C. H. Nightingale. 1996. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. 40: 2375-2379.
40. Rodvold, K. A., M. H. Gotfried, L. H. Danziger, and R. J. Servi. 1997. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother. 41:1399-1402.
41. Rostand, K. S., and J. D. Esko. 1997. Microbial adherence to and invasion through proteoglycans. Infect. Immun. 65:1-8.
42. Sakata, K., H. Yajima, K. Tanaka, Y. Sakamoto, K. Yamamoto, A. Yoshida, and Y. Dohi. 1993. Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro. Am. Rev. Respir. Dis. 148:1061-1065.
43. Suzaki, H., K. Asano, S. Ohki, K. Nanai, T. Mizutani, and T. Hisamitsu. 1999. Suppressive activity of a macrolide antibiotic, roxithromycin, on proinflammatory cytokine production in vitro and in vivo. Mediators Inflamm. 8:199-204.
44. Takizawa, H., M. Desaki, T. Ohtoshi, S. Kawasaki, T. Kohyama, M. Sato, M. Tanaka, T. Kasama, K. Kobayashi, J. Nakajima, and K. Ito. 1997. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am. J. Respir. Crit. Care Med. 156:266-271.
45. Tateda, K., Y. Ishii, T. Matsumoto, T. Kobayashi, S. Miyazaki, and K. Yamaguchi. 2000. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response. J. Infect. Chemother. 6:1-7.
46. Thatcher, T. H., N. A. McHugh, R. W. Egan, R. W. Chapman, J. A. Hey, C. K. Turner, M. R. Redonnet, K. E. Seweryniak, P. J. Sime, and R. P. Phipps. 2005. Role of CXCR2 in cigarette smoke-induced lung inflammation. Am. J. Physiol. Lung Cell. Mol. Physiol. 289:L322-L328.
47. Wilson, C. L., K. J. Heppner, L. A. Rudolph, and L. M. Matrisian. 1995. The metalloproteinase matrilysin is preferentially expressed by epithelial cells in a tissue-restricted pattern in the mouse. Mol. Biol. Cell 6:851-869.